Relapsed/refractory classical Hodgkin lymphoma effectively treated with low-dose decitabine plus tislelizumab: A case report

BACKGROUND: Academic studies have proved that anti-programmed death-1 (PD-1) monoclonal antibodies demonstrated remarkable activity in relapsed/refractory classical Hodgkin lymphoma (cHL). However, most patients ultimately experienced failure or resistance. It is urgent and necessary to develop a no...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Xiao-Sheng, Mi, Lan, Song, Yu-Qin, Liu, Wei-Ping, Yu, Hui, Lin, Ning-Jing, Zhu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316945/
https://www.ncbi.nlm.nih.gov/pubmed/34368325
http://dx.doi.org/10.12998/wjcc.v9.i21.6041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316945/
https://www.ncbi.nlm.nih.gov/pubmed/34368325
http://dx.doi.org/10.12998/wjcc.v9.i21.6041

Ejemplares similares